At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown. We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. The median duration of viral RNA shedding was shorter in the FV (12 [IQR, 9.5–14] days) and PV (13 [IQR, 9–16.75] days) groups than in the UV group (15 [IQR, 11.75–17.25] days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co [IQR, 2.08–63.59] and 0.3 S/co [IQR, 0.05–2.29], respectively) and PV (0.68 S/co [IQR, 0.14–28.69] and 0.12 S/co [0.03–5.23], respectively) groups than in the UV group (0.06 S/co [IQR, 0.03–0.47] and 0.04 S/co [IQR, 0.02–0.07]) (adjusted P < 0.001 and adjusted P = 0.008, respectively). Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection.
Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) is a severe clinical syndrome with a high mortality rate. Identifying prognostic factors is therefore crucial. This study aimed to identify factors influencing the prognosis of HBV-ACLF and to construct a combined prognostic indicator. This retrospective study included 258 patients with HBV-ACLF, categorized into 2 groups based on prognosis: improvement and worsening. Baseline characteristics, biochemical parameters, and hematological indicators were compared between the 2 groups. Multiple logistic regression and a support vector machine model were applied to analyze the factors associated with prognosis. Based on the regression results, a composite indicator was developed and its predictive performance was evaluated using receiver operating characteristic curve analysis. The incidence of complications such as advanced age, esophageal varices, severe jaundice, and severe ascites was significantly higher in the prognosis worsening group than in the improvement group. Biochemical and hematological indicators such as ammonia (NH₃), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were significantly elevated in the worsening group, while albumin levels were significantly lower compared with the improvement group. Analysis indicated that ALT, AST, LDH, NH₃, and model for end-stage liver disease score were most strongly associated with prognosis. The receiver operating characteristic curve of the combined indicator showed an area under the curve of 0.749, outperforming any single indicator. In addition, the combined index was significantly negatively correlated with the length of hospital stay. ALT, AST, LDH, NH₃, and model for end-stage liver disease score are key prognostic factors in patients with HBV-ACLF. The combined indicator constructed from these variables demonstrates good predictive value for clinical outcomes and length of hospital stay, and may provide useful guidance for clinical decision-making.
Background: Understanding of the early immune response in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) breakthrough infections is limited.Methods: Ninety‐eight patients with coronavirus disease 2019 (COVID‐19) breakthrough infections were divided into two groups, with intervals from receiving the second dose of inactivated vaccine to the onset of illness <60 or ≥60 days.Results: The median lymphocyte count and the median anti‐SARS‐CoV‐2 spike immunoglobulin G (IgG) and immunoglobulin M (IgM) titers were higher in the <60‐day interval group compared with the corresponding medians in the ≥60‐day interval group (p = 0.005, p = 0.001, and p = 0.001, respectively). The median interleukin‐6 (IL‐6) level in the <60‐day interval group was significantly lower than the median IL‐6 level in the ≥60‐day interval group (p < 0.001).Conclusions: Our results highlight the different anti‐SARS‐CoV‐2 spike IgG and IgM antibody titers among patients with different intervals from receiving the second dose of inactivated vaccine to the onset of illness.